Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Glycopeptide-cephalosporin heterodimer (TD-1792); Heterodimer antibacterial - Theravance Biopharma; TD-1792

Latest Information Update: 23 Mar 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline; Theravance
  • Developer R-Pharm; Theravance Biopharma
  • Class Acetamides; Antibacterials; Azabicyclo compounds; Beta-lactams; Cephalosporins; Peptide antibiotics; Pyridines; Thiazoles
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Skin and soft tissue infections

Most Recent Events

  • 17 Jun 2015 Phase II development is ongoing the USA
  • 02 Jun 2014 Theravance Biopharma is formed as a spin-off of Theravance
  • 31 Oct 2012 Theravance granted R-Pharm exclusive development and commercialisation rights to TD 1792 in the Russian Federation, Ukraine, other countries of the Commonwealth of Independent States and Georgia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top